Avoid Rexulti (Brexpiprazole) in This Patient
Given this patient's history of akathisia from both aripiprazole (Abilify) and lurasidone (Latuda), I strongly recommend against trying brexpiprazole (Rexulti) due to the high likelihood of recurrent akathisia. All three medications share similar mechanisms that predispose to akathisia, and cross-reactivity is highly probable.
Why Brexpiprazole Will Likely Cause Akathisia Again
Shared Pharmacological Mechanisms
Brexpiprazole is pharmacologically very similar to aripiprazole—both are dopamine D2 receptor partial agonists with high receptor affinity 1. While brexpiprazole was designed with "lower intrinsic D2 activity" theoretically suggesting less akathisia than aripiprazole 2, the clinical reality contradicts this marketing claim:
- Brexpiprazole's akathisia incidence is 10.0% (95% CI 7.4-13.5%) across clinical trials 1
- The odds ratio for akathisia with brexpiprazole versus placebo is 2.04, meaning it more than doubles akathisia risk 1
- Importantly, brexpiprazole shows higher akathisia rates than iloperidone and asenapine, though lower than lurasidone (12.7%) and cariprazine (17.2%) 1
Cross-Sensitivity Pattern
Your patient has already demonstrated akathisia with:
- Aripiprazole (a D2 partial agonist)
- Lurasidone (a serotonin-dopamine activity modulator)
This pattern suggests the patient has heightened sensitivity to medications affecting dopaminergic pathways in the basal ganglia 3. Recent evidence shows that even low, introductory doses of these agents can precipitate severe akathisia in susceptible individuals 4.
Alternative Treatment Strategies for Bipolar I
First-Line Options Without High Akathisia Risk
Based on FDA-approved treatments for Bipolar I disorder 5:
Mood Stabilizers (Preferred):
- Lithium (FDA-approved for acute mania and maintenance)
- Valproate/Divalproex (FDA-approved for acute mania)
- Lamotrigine (FDA-approved for maintenance therapy)
Atypical Antipsychotics with Lower Akathisia Risk:
- Quetiapine (FDA-approved for acute mania)
- Olanzapine (FDA-approved for acute mania and maintenance)
- Note: Monitor metabolic parameters closely
- Risperidone (FDA-approved for acute mania)
- Lower akathisia risk than partial agonists, though still present
Avoid These Medications in Your Patient
Do not use:
- Brexpiprazole (Rexulti) - as discussed
- Cariprazine - highest akathisia rate at 17.2% 1, 6
- Any other D2 partial agonist
Clinical Pearls and Pitfalls
Common Mistake to Avoid
Clinicians sometimes assume that because brexpiprazole is "newer" or marketed as having "lower activation" than aripiprazole, it will be tolerated by patients who failed aripiprazole. This is incorrect. The high D2 receptor affinity shared by both agents makes cross-reactivity highly likely 7.
If Akathisia Develops
Should you inadvertently prescribe an agent that causes akathisia:
- Discontinue immediately - symptoms typically resolve completely upon discontinuation 4
- Consider benzodiazepines (e.g., clonazepam) for acute management 3
- Beta-blockers (propranolol) or anticholinergics may provide symptomatic relief
Monitoring Strategy
When initiating any new antipsychotic in this patient:
- Start at the lowest possible dose
- Monitor closely for subjective restlessness within the first 1-2 weeks
- Use objective scales (Barnes Akathisia Rating Scale) if available
- Educate patient to report inner restlessness immediately
Recommended Approach
For acute mania: Start with lithium or valproate monotherapy, or consider quetiapine if an antipsychotic is specifically needed 5.
For maintenance: Lithium, lamotrigine, or olanzapine are FDA-approved options 5.
For bipolar depression: Consider lamotrigine, quetiapine, or the olanzapine-fluoxetine combination rather than lurasidone (which already failed) 5.
The patient's medication history clearly indicates vulnerability to akathisia with dopamine partial agonists and related mechanisms. Prioritize mood stabilizers or antipsychotics with different receptor profiles to optimize both efficacy and tolerability 5.